- Home
- GNTA vs CNTB Comparison
GNTA vs CNTB Comparison
Compare GNTA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | CNTB |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.7M | 140.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNTA | CNTB |
|---|---|---|
| Price | $0.72 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 37.2K | ★ 1.5M |
| Earning Date | 03-24-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.55 | $1.23 |
| 52 Week High | $10.00 | $3.82 |
Technical Indicators
Market Signals| Indicator | GNTA | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 31.79 |
| Support Level | $0.58 | N/A |
| Resistance Level | $0.91 | $2.78 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | -0.00 | -0.11 |
| Stochastic Oscillator | 16.79 | 10.62 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.